MRMD تصريحات هيئة الأوراق المالية والبورصات - MariMed Inc.- التقرير السنوي، بيان التوكيل، نشرة الإصدار

الإحصائيات الأساسية

CIK

1522767

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to MariMed Inc.

SEC Filings (Chronological Order)

توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.

August 7, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended June 30, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 MARIMED I
August 6, 2025	EX-99.1	MariMed Reports Second Quarter 2025 Earnings Exhibit 99.1 MariMed Reports Second Quarter 2025 Earnings NORWOOD, MA, August 6, 2025 - MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for the second quarter ended June 30, 2025. Management Commentary “We delivered growth and expanded operations across our busin
August 6, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 MARIMED INC. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction of incorporation) (Commission File Number)
June 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 MARIMED INC. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction of incorporation) (Commission File Number) (
May 8, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended March 31, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 MARIMED
May 7, 2025	EX-99.1	MariMed Reports First Quarter 2025 Earnings Exhibit 99.1 MariMed Reports First Quarter 2025 Earnings NORWOOD, MA, May 7, 2025 - MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for the first quarter ended March 31, 2025. Management Commentary “We are executing on our vision to build the best consumer packag
May 7, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction of incorporation) (Commission File Number) (IR
April 30, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEF 14A 1 proxydocument20252024finan.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for use of the Commission Only (as permit
March 6, 2025	EX-19.1	Insider Trading Policy of the Registrant. Exhibit 19.1 MARIMED INC. POLICY ON INSIDER TRADING AND DISCLOSURE OF MATERIAL NONPUBLIC INFORMATION (As revised on June 8, 2023) In the course of conducting the business of MariMed Inc. (the “Company”), you may come into possession of material information about the Company or other entities that is not available to the investing public (“material nonpublic information”). You must maintain the con
March 6, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 MARIMED INC. (Exact
March 6, 2025	EX-21.1	Subsidiaries of the Registrant Exhibit 21.1 MariMed Inc. Subsidiaries of the Registrant Name Jurisdiction of Incorporation MariMed Advisors Inc. Massachusetts Mia Development LLC Massachusetts Mari Holdings IL LLC Massachusetts Mari Holdings MD LLC Massachusetts Mari Holdings NJ LLC New Jersey Mari Holdings NV LLC Massachusetts Mari Holdings Metropolis LLC Massachusetts Mari Holdings Mt. Vernon LLC Massachusetts Mari Mfg LLC Ne
March 5, 2025	EX-99.1	MariMed Reports Fourth Quarter and Full Year 2024 Earnings Exhibit 99.1 MariMed Reports Fourth Quarter and Full Year 2024 Earnings NORWOOD, MA, March 5, 2025 - MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for the fourth quarter and year ended December 31, 2024. MariMed CEO Jon Levine commented, “We’re pleased to repor
March 5, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2025 MARIMED INC. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2025 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction of incorporation) (Commission File Number) (
November 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended September 30, 2024 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 MARI
November 6, 2024	EX-99.1	MariMed Reports Third Quarter 2024 Earnings Exhibit 99.1 MariMed Reports Third Quarter 2024 Earnings NORWOOD, MA, November 6, 2024 - MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for the third quarter ended September 30, 2024. “We reported year-over-year and sequential revenue growth, sequential EBITDA a
November 6, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction of incorporation) (Commission File Number
August 9, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2024 MARIMED INC. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2024 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction of incorporation) (Commission File Number)
August 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended June 30, 2024 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 MARIMED I
August 8, 2024	EX-4.1	Common Stock Purchase Warrant dated May 2, 2024 issued by the Company to Change Equity Capital LLC. /s/ Frank Segall
August 8, 2024	EX-3.2	Amended and Restated By-Laws, effective as of August 5, 2024 (incorporated by reference to Exhibit 3.2 to the Company's Quarterly Report on Form 10-Q, filed on August 8, 2024 with the SEC). AMENDED AND RESTATED BY-LAWS OF MARIMED INC. (hereinafter called the "Corporation") ARTICLE I OFFICES Section 1. Registered Office. The registered office of the Corporation shall be in the City of Wilmington, County of New Castle, State of Delaware. Section 2. Other Offices. The Corporation may also have offices at such other places both within and without the State of Delaware as the Board of Dir
August 7, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction of incorporation) (Commission File Number)
August 7, 2024	EX-99.1	MariMed Reports Second Quarter 2024 Earnings Exhibit 99.1 MariMed Reports Second Quarter 2024 Earnings NORWOOD, MA, August 7, 2024 - MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for the second quarter ended June 30, 2024. “With the first half of the year in the books, I’m pleased to say we remain on trac
June 6, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction of incorporation) (Commission File Number) (I
May 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended March 31, 2024 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 MARIMED
May 8, 2024	EX-99.1	MariMed Reports First Quarter 2024 Earnings Exhibit 99.1 MariMed Reports First Quarter 2024 Earnings NORWOOD, MA, May 8, 2024 - MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for the first quarter ended March 31, 2024. “With the first quarter now in the books, I’m pleased to say we are on track with our s
May 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 MARIMED INC. (Exact n UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction of incorporation) (Commission File Number) (IR
April 29, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e) (2) x Definitive Proxy State
March 7, 2024	10-K	. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) Table of Contents . UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433
March 7, 2024	EX-21.1	Subsidiaries of the Registrant Exhibit 21.1 MariMed Inc. Subsidiaries of the Registrant Name Jurisdiction of Incorporation MariMed Advisors Inc. Massachusetts Mia Development LLC Massachusetts Mari Holdings IL LLC Massachusetts Mari Holdings MD LLC Massachusetts Mari Holdings NJ LLC New Jersey Mari Holdings NV LLC Massachusetts Mari Holdings Metropolis LLC Massachusetts Mari Holdings Mt. Vernon LLC Massachusetts Mari Mfg LLC Ne
March 6, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2024 MARIMED INC. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2024 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction of incorporation) (Commission File Number) (
March 6, 2024	EX-99.1	MariMed Reports Fourth Quarter and Full Year 2023 Earnings Announces Expansion of Maryland Footprint With Pending Acquisition of Dispensary in Upper Marlboro Exhibit 99.1 MariMed Reports Fourth Quarter and Full Year 2023 Earnings Announces Expansion of Maryland Footprint With Pending Acquisition of Dispensary in Upper Marlboro NORWOOD, MA, March 6, 2024 - MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for the fourth
November 20, 2023	EX-10.1	Construction Loan Agreement, dated November 16, 2023, by and among Mari Holdings MD LLC, Hartwell Realty Holdings LLC, Kind Therapeutics USA, LLC, ARL Healthcare Inc. and MariMed Advisors Inc., and Needham Bank (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K, filed November 20, 2023 with the SEC). Exhibit 10.1 CONSTRUCTION LOAN AGREEMENT This CONSTRUCTION LOAN AGREEMENT (as the same may be amended, restated, modified, substituted or extended from time to time, this “Agreement”) is made as of this 16th day of November, 2023 (the “Closing Date”), by and among (i) MARI HOLDINGS MD LLC, a Massachusetts limited liability company (“MD Owner”), (ii) HARTWELL REALTY HOLDINGS LLC, a Massachusetts li
November 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2023 MARIMED INC. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2023 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction of incorporation) (Commission File Numbe
November 20, 2023	EX-99.1	MariMed Closes $58.7 Million Debt Refinancing 10-Year Term at Reduced Annualized Interest Rate Will Result in $4.7 Million Reduction to Principal and Interest Expense in the First 12 Months and $3.5 Million Annually for Next Four Years and Includes N Exhibit 99.1 MariMed Inc. 10 Oceana Way, 2nd Floor Norwood, MA 02062 MariMed Closes $58.7 Million Debt Refinancing 10-Year Term at Reduced Annualized Interest Rate Will Result in $4.7 Million Reduction to Principal and Interest Expense in the First 12 Months and $3.5 Million Annually for Next Four Years and Includes No Equity Component NORWOOD, Mass., November 20, 2023 – MariMed Inc. (“MariMed” or
November 20, 2023	EX-4.1	[FORM OF] PROMISSORY NOTE Exhibit 4.1 [FORM OF] PROMISSORY NOTE $58,695,000.00 Dated: November 16, 2023 FOR VALUE RECEIVED, (i) MARI HOLDINGS MD LLC, a Massachusetts limited liability company, (ii) HARTWELL REALTY HOLDINGS LLC, a Massachusetts limited liability company, (iii) KIND THERAPEUTICS USA, LLC, a Maryland limited liability company, (iv) ARL HEALTHCARE INC., a Massachusetts corporation, and (v) MARIMED ADVISORS INC
November 20, 2023	EX-10.2	Construction Loan Agreement, dated November 16, 2023, by and among Mari Holdings MD LLC, Hartwell Realty Holdings LLC, Kind Therapeutics USA, LLC, ARL Healthcare Inc., and MariMed Advisors, Inc., and Needham Bank. Exhibit 10.2 [FORM OF] PAYMENT GUARANTY This PAYMENT GUARANTY (this “Guaranty”) is made as of the 16th day of November, 2023, by MARIMED INC., a Delaware corporation (“Guarantor,” which expression shall include Guarantor’s heirs, successors and assigns), having an address of 10 Oceana Way, Norwood, Massachusetts 02062, for the benefit of NEEDHAM BANK, a Massachusetts co-operative bank, having an a
November 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended September 30, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 MARI
November 8, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction of incorporation) (Commission File Number
November 8, 2023	EX-99.1	MariMed Reports Third Quarter 2023 Earnings Exhibit 99.1 MariMed Reports Third Quarter 2023 Earnings NORWOOD, MA, November 8, 2023 - MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for the third quarter ended September 30, 2023. “I am pleased to report another solid quarter of strong revenue growth on both
November 3, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction of incorporation) (Commission File Number
November 3, 2023	EX-99.1	October 31, 2023 Exhibit 99.1 MariMed Inc. 10 Oceana Way, 2nd Floor Norwood, MA 02062 Phone: 781-277-0007 October 31, 2023 Dear Jon Levine and David Allen: I resign my position as Chief Financial Officer of MariMed Inc. and any other position I may hold in MariMed or any of its affiliates effective immediately. Kind Regards, /s/ Susan M. Villare Susan M. Villare
August 4, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended June 30, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 MARIMED I
August 4, 2023	EX-10.2	Omnibus Agreement, dated July 1, 2023, by and between MariMed Inc., MariMed Advisors Inc., MIA Development LLC, and First State Compassion Center, Inc. OMNIBUS AGREEMENT This OMNIBUS AGREEMENT (this “Agreement”) is entered into as of July 1, 2023 by and between MARIMED INC.
August 4, 2023	EX-10.1	MariMed Inc. Second Amended and Restated 2018 Stock Award and Incentive Plan, as amended and restated June 8, 2023 (incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q, filed August 4, 2023 with the SEC). MARIMED, INC. SECOND AMENDED AND RESTATED 2018 STOCK AWARD AND INCENTIVE PLAN (Amended and Restated June 8, 2023) ARTICLE I PURPOSE 1.1 Purpose. The purpose of the MariMed, Inc. 2018 Amended and Restated Stock Award and Incentive Plan (as may be amended from time to time, the “Plan”) is to strengthen the ability of MariMed, Inc. (the “Company”) to attract, motivate, and retain employees, directors
August 2, 2023	EX-99.1	MariMed Reports Second Quarter 2023 Earnings Exhibit 99.1 MariMed Reports Second Quarter 2023 Earnings NORWOOD, MA, August 2, 2023 - MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for the second quarter ended June 30, 2023. “I am pleased to report another solid quarter of accelerating revenue growth on bot
August 2, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 MARIMED INC. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction of incorporation) (Commission File Number)
June 12, 2023	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction of incorporation) (Commission File Number) (I
May 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended March 31, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 MARIMED
May 9, 2023	EX-3.2	Amended By-Laws, amended as of February 28, 2023 (incorporated by reference to Exhibit 3.2 to the Company's Quarterly Report on Form 10-Q, filed on May 9, 2023 with the SEC). Exhibit 3.2 AMENDED BY-LAWS OF MARIMED INC. (hereinafter called the "Corporation") ARTICLE I OFFICES Section 1. Registered Office. The registered office of the Corporation shall be in the City of Wilmington, County of New Castle, State of Delaware. Section 2. Other Offices. The Corporation may also have offices at such other places both within and without the State of Delaware as the Board of Dire
May 8, 2023	EX-99.1	MariMed Reports First Quarter 2023 Earnings Exhibit 99.1 MariMed Reports First Quarter 2023 Earnings NORWOOD, MA, May 8, 2023 - MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for the first quarter ended March 31, 2023. “I am pleased to report another solid quarter,” said Jon Levine, Chief Executive Office
May 8, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction of incorporation) (Commission File Number) (IR
April 27, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e) (2) x Definitive Proxy State
April 17, 2023	EX-99.1	MariMed Expands Board With the Addition of Kathleen Tucker Exhibit 99.1 MariMed Expands Board With the Addition of Kathleen Tucker NORWOOD, MA, April 17, 2023 - MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator ("MSO"), today announced that Kathleen Tucker has been appointed to the Company's Board of Directors. Ms. Tucker has more than 25 years of senior executive experience in consumer marketing,
April 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 MARIMED INC. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction of incorporation) (Commission File Number)
March 7, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) MARIMED INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (2) Minimum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par valu
March 7, 2023	S-8	As filed with the United States Securities and Exchange Commission on March 7, 2023 As filed with the United States Securities and Exchange Commission on March 7, 2023 Registration No.
March 6, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 MARIMED INC. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction of incorporation) (Commission File Numbe
March 6, 2023	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433
March 6, 2023	EX-3.2(A)	Amendment to the Corporation's Bylaws. Exhibit 3.2(A) AMENDMENT TO THE BYLAWS OF MARIMED INC. Adopted and Approved February 28, 2023 (this “Amendment”) 1. Article IV, Sections 4 and 5 of the MariMed Inc. Bylaws (the “Bylaws”) is amended to read as follows: Section 4. Chairman of the Board of Directors. The Chairman of the Board of Directors, if there be one, shall preside at all meetings of the stockholders and of the Board of Director
March 3, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 MA
March 3, 2023	EX-21.1	MariMed Inc. Subsidiaries of the Registrant Exhibit 21.1 MariMed Inc. Subsidiaries of the Registrant Name Jurisdiction of Incorporation MariMed Advisors Inc. Massachusetts Mia Development LLC Massachusetts Mari Holdings IL LLC Massachusetts Mari Holdings MD LLC Massachusetts Mari Holdings NJ LLC New Jersey Mari Holdings NV LLC Massachusetts Mari Holdings Metropolis LLC Massachusetts Mari Holdings Mt. Vernon LLC Massachusetts Mari Mfg LLC Ne
March 3, 2023	EX-10.18	Amended and Restated Employment Agreement, effective as of February 28, 2023, between the Registrant and Jon R. Levine (incorporated by reference to Exhibit 10.18 to the Registrant's Annual Report on Form 10-K, as amended, filed March 3, 2023 with the SEC). February 28, 2023 Jon R. Levine MariMed Inc. 10 Oceana Way Norwood, Massachusetts 02062 RE: Amended and Restated Employment Letter Agreement Dear Jon: On behalf of MariMed Inc. (the “Company” or “MariMed”), this letter (the “Agreement”) sets forth the terms and conditions of your continued employment with the Company in the capacity of its Chief Executive Officer and President. This Agreement shal
March 3, 2023	EX-10.23	Form of Stock Option Agreement under the Amended and Restated 2018 Stock Award and Incentive Plan, as Amended (incorporated by reference to Exhibit 10.23 to the Registrant's Annual Report on Form 10-K, as amended, filed March 3, 2023 with the SEC). MARIMED INC. AMENDED AND RESTATED 2018 STOCK AWARD AND INCENTIVE PLAN, AS AMENDED Non-Statutory Stock Option Award Agreement This NON-STATUTORY STOCK OPTION AWARD AGREEMENT (the “Agreement”) is made effective as of (the “Grant Date”), between MariMed Inc., a Delaware corporation (the “Company”), and (the “Participant” or “you”). RECITALS WHEREAS, the Company has adopted the Amended and Restated 20
March 3, 2023	EX-10.22	Amended and Restated 2018 Stock Award and Incentive P MARIMED INC. AMENDED AND RESTATED 2018 STOCK AWARD AND INCENTIVE PLAN, AS AMENDED Restricted Stock Unit Agreement (Time-Based Vesting) This Restricted Stock Unit Agreement (the "Agreement") is made effective as of (the "Grant Date") between MariMed Inc., a Delaware corporation (the "Company") and (the "Participant"). RECITALS WHEREAS, the Company has adopted the Amended and Restated 2018 Stock Awa
March 3, 2023	EX-10.19	Amended and Restated Employment Agreement, effective as of February 28, 2023, between the Registrant and Susan M. Villare (incorporated by reference to Exhibit 10.19 to the Registrant's Annual Report on Form 10-K, as amended, filed March 3, 2023 with the SEC). February 28, 2023 Susan M. Villare MariMed Inc. 10 Oceana Way Norwood, Massachusetts 02062 RE: Amended and Restated Employment Letter Agreement Dear Susan: On behalf of MariMed Inc. (the “Company” or “MariMed”), this letter (the “Agreement”) sets forth the terms and conditions of your continued employment with the Company in the capacity of its Chief Financial Officer. This Agreement shall amend a
March 3, 2023	EX-10.20	Amended and Restated Employment Agreement, effective as of February 28, 2023, between the Registrant and Timothy Shaw (incorporated by reference to Exhibit 10.20 to the Registrant's Annual Report on Form 10-K, as amended, filed March 3, 2023 with the SEC). February 28, 2023 Timothy Shaw MariMed Inc. 10 Oceana Way Norwood, Massachusetts 02062 RE: Amended and Restated Employment Letter Agreement Dear Timothy: On behalf of MariMed Inc. (the “Company” or “MariMed”), this letter (the “Agreement”) sets forth the terms and conditions of your continued employment with the Company in the capacity of its Chief Operating Officer. This Agreement shall amend and
March 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 MARIMED INC. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction of incorporation) (Commission File Number) (
March 1, 2023	EX-99.1	MariMed Reports Fourth Quarter and Full Year 2022 Financial Results Exhibit 99.1 MariMed Reports Fourth Quarter and Full Year 2022 Financial Results NORWOOD, MA, March 1, 2023 - MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for the fourth quarter and full year ended December 31, 2022. “I am pleased to report that our fourth qua
January 24, 2023	EX-4.2	Form of Promissory Note, dated January 24, 2023, issued by the Registrant and the subsidiaries of the Registrant party thereto to Chicago Atlantic Credit Company, LLC (incorporated by reference to Exhibit 4.2 to the Registrant's Current Report on Form 8-K, filed January 24, 2023 with the SEC). Exhibit 4.2 THE LOAN EVIDENCED BY THIS NOTE HAS BEEN ISSUED WITH AN ORIGINAL ISSUE DISCOUNT FOR UNITED STATES FEDERAL INCOME TAX PURPOSES. THE ISSUE PRICE, AMOUNT OF SUCH ORIGINAL ISSUE DISCOUNT, ISSUE DATE AND YIELD TO MATURITY OF THIS LOAN MAY BE OBTAINED BY WRITING TO ADMINISTRATIVE AGENT. [FORM OF] PROMISSORY NOTE $[PRINCIPAL AMOUNT] January 24, 2023 FOR VALUE RECEIVED, each of the undersigned
January 24, 2023	EX-10.1	Loan and Security Agreement, dated as of January 24, 2023, by and among the Registrant, certain subsidiaries of the Registrant (the "Borrowers") from time-to-time party thereto, certain lenders from time-to-time party thereto (the "Lenders"), and Chicago Atlantic Admin, LLC, a Delaware limited liability company as administrative agent for the Lenders (incorporated by reference to the Registrant's Current Report on Form 8-K, filed January 24, 2023 with the SEC). Exhibit 10.1 THE PARTIES HERETO ACKNOWELDGE THAT ANY CHANGE OF OWNERSHIP OR CONTROL, OR TRANSFER OF CANNABIS AND CANNABIS RELATED ASSETS THAT COULD RESULT FROM AN EXERCISE OF CERTAIN REMEDIES HEREUNDER SHALL BE SUBJECT TO COMPLIANCE WITH US STATE CANNABIS LAWS AND REGULATIONS WHICH MAY REQUIRE CONSENT OF THE APPLICABLE STATE REGULATORY AUTHORITIES. LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURIT
January 24, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2023 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction of incorporation) (Commission File Number
January 24, 2023	EX-4.1	Form of Common Stock Purchase Warrant, dated January 24, 2023, issued by the Registrant to the lenders (incorporated by reference to Exhibit 4.1 to the Registrant's Current Report on Form 8-K, filed January 24, 2023 with the SEC). Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
January 24, 2023	EX-99.1	MariMed Closes $35 Million Credit Facility to Accelerate its Strategic Growth Plans Exhibit 99.1 MariMed Closes $35 Million Credit Facility to Accelerate its Strategic Growth Plans NORWOOD, MA, Jan 24, 2023 - MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator, announced that today it closed a $35 million secured credit facility with Chicago Atlantic Advisors, LLC (“Chicago Atlantic”) as the lead lender. “I am delighted to
December 14, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2022 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction of incorporation) (Commission File Numbe
December 14, 2022	EX-99.1	MariMed Appoints Jon Levine as Interim Chief Executive Officer Exhibit 99.1 MariMed Appoints Jon Levine as Interim Chief Executive Officer NORWOOD, MA, December 14, 2022 - MariMed, Inc. (?MariMed? or the ?Company?) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its Board of Directors (the ?Board?) appointed Jon Levine, MariMed?s President, as Interim Chief Executive Officer. ?With a hea
December 12, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2022 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction of incorporation) (Commission File Numbe
December 12, 2022	EX-99.1	MariMed Mourns the Passing of Robert Fireman, Chairman, CEO And Cannabis Industry Pioneer and Visionary Exhibit 99.1 MariMed Mourns the Passing of Robert Fireman, Chairman, CEO And Cannabis Industry Pioneer and Visionary NORWOOD, MA, December 12, 2022 - MariMed Inc. (?MariMed? or the ?Company?) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced with deep sadness that Chairman, Chief Executive Officer, and co-founder Robert Fireman
November 8, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended September 30, 2022 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 MARI
November 7, 2022	EX-99.1	MariMed Reports Third Quarter 2022 Earnings EX-99.1 2 marimed-20221107xex991.htm EX-99.1 Exhibit 99.1 MariMed Reports Third Quarter 2022 Earnings NORWOOD, MA, November 7, 2022 - MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for the third quarter ended September 30, 2022. “I am pleased to report we grew r
November 7, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 MARIMED INC. (Ex UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction of incorporation) (Commission File Number
October 31, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2022 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporatio
September 22, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e) (2) ? Definitive Proxy State
September 7, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2022 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporati
September 7, 2022	EX-99.1	MariMed Appoints Jon Levine as President Exhibit 99.1 MariMed Appoints Jon Levine as President NORWOOD, Mass., September 7, 2022 ? MariMed, Inc. (CSE: MRMD), (OTCQX: MRMD) (?MariMed? or the ?Company?), a leading multi-state cannabis operator (?MSO?) focused on improving lives every day, today announced the appointment of Jon Levine as President, effective immediately. Mr. Levine co-founded MariMed with Chief Executive Officer Bob Fireman
September 7, 2022	EX-10.1	Form of Third Amendment to Employment Agreement, effective as of September 7, 2022, between MariMed Inc. and Jon R. Levine. Exhibit 10.1 MariMed Inc. THIRD AMENDMENT TO EMPLOYMENT AGREEMENT Effective Date: September 7, 2022 This Third Amendment to the Employment Agreement (this ?Agreement?) is between MARIMED INC., a Delaware corporation (the ?Company? or ?MariMed?), and JON R. LEVINE, an individual (the ?Executive?). WHEREAS, the Company and the Executive entered into an Employment Agreement effective as of dated July
August 9, 2022	EX-10.4	Second Amendment to Securities Purchase Agreement, dated August 4, 2022 by and between MariMed Inc. and Hadron Healthcare Master Fund (incorporated by reference to Exhibit 4.2 to the Registrant's Quarterly Report on Form 10-Q, filed August 9, 2022 with the SEC). Exhibit 10.4
August 9, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 MARIMED INC. (Exact Name of
August 8, 2022	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporation)
August 8, 2022	EX-99.1	MariMed Reports Second Quarter 2022 Earnings Exhibit 99.1 MariMed Reports Second Quarter 2022 Earnings NORWOOD, MA, August 8, 2022 - MariMed, Inc. (?MariMed? or the ?Company?) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for the second quarter ended June 30, 2022. ?We executed on our strategic plan, growing revenue both year-over-year and sequen
May 18, 2022	EX-10.2	Stock Option Agreement, dated May 2, 2022, between the Registrant and Susan M. Villare (incorporated by reference to Exhibit 10.2 to the Registrant's Current Report on Form 8-K filed May 18, 2022 with the SEC). Exhibit 10.2 MARIMED INC. Stock Option Agreement (this ?Agreement?) Dated: May 2, 2022 (?Grant Date?) MariMed Inc., a Delaware corporation (the ?Company?), in accordance with the Company?s Amended and Restated 2018 Stock Award and Incentive Plan (the ?Plan?) hereby grants to Susan Villare (the ?Optionee?), a stock option to purchase a total of 400,000 shares of the Company?s Common Stock, par valu
May 18, 2022	EX-10.3	Restricted Stock Agreement, dated May 2, 2022, between the Registrant and Susan M. Villare (incorporated by reference to Exhibit 10.3 to the Registrant's Current Report on Form 8-K, filed May 18, 2022 with the SEC). Exhibit 10.3 RESTRICTED STOCK GRANT AGREEMENT THIS RESTRICTED STOCK AGREEMENT (this ?Agreement?) is made as of the 2nd day of May 2022 by and between Susan Villare (the ?Employee?) and Marimed Inc., a Delaware corporation (the ?Corporation?). WHEREAS, the Compensation Committee of the Board of Directors of the Corporation (the ?Committee?) (or a designated successor to such committee) at its meeti
May 18, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporation) F
May 18, 2022	EX-10.1	Form of Second Amendment to Agreement to Employment, effective as of May 11, 2022, between MariMed Inc. and Jon R. Levine (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on May 18, 2022 with the SEC). Exhibit 10.1 MariMed Inc. SECOND AMENDMENT TO EMPLOYMENT AGREEMENT Effective Date: May 12, 2022 This Second Amendment to the Employment Agreement (this ?Agreement?) is between MARIMED INC., a Delaware corporation (the ?Company? or ?MariMed?), and JON R. LEVINE, an individual (the ?Executive?). WHEREAS, the Company and the Executive entered into an Employment Agreement effective as of dated July 1,
May 16, 2022	EX-99.2	Transcript of investor conference call held on May 11, 2022. Exhibit 99.2
May 16, 2022	EX-99.1	MariMed Reports First Quarter 2022 Earnings Revenue Grew 27% Year Over Year Non-GAAP Adjusted EBITDA Grew 29% Year Over Year Company Maintains Full Year 2022 Guidance Exhibit 99.1 MariMed Reports First Quarter 2022 Earnings Revenue Grew 27% Year Over Year Non-GAAP Adjusted EBITDA Grew 29% Year Over Year Company Maintains Full Year 2022 Guidance NORWOOD, MA, May 10, 2022 - MariMed, Inc. (OTCQX: MRMD) (?MariMed? or the ?Company?), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for the first quar
May 16, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporation) F
May 16, 2022	EX-99.3	Investor Presentation, dated May 10, 2022 EX-99.3 4 ex99-3.htm Exhibit 99.3
May 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 MARIMED INC. (Exact Name o
April 14, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2022 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporation)
April 14, 2022	EX-99.1	MariMed Receives Maryland State Approval for Transfer of Ownership of Kind Therapeutics USA Exhibit 99.1 MariMed Receives Maryland State Approval for Transfer of Ownership of Kind Therapeutics USA NORWOOD, Mass., April 14, 2022 ? MariMed Inc. (OTCQX: MRMD) (?MariMed? or the ?Company?), a leading multi-state cannabis operator focused on improving lives every day, today announced that the Maryland Medical Cannabis Commission (MMCC) has approved the transfer of 100% of the ownership of Kind
March 21, 2022	8-K	Regulation FD Disclosure, Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2022 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporation)
March 21, 2022	EX-99.2	MariMed Inc. Fourth Quarter 2021 Financial Results Conference Call March 17, 2022 — 8:00 a.m. E.T. Length: 45 minutes Exhibit 99.2 MariMed Inc. Fourth Quarter 2021 Financial Results Conference Call March 17, 2022 ? 8:00 a.m. E.T. Length: 45 minutes Corporate participants Steve West MariMed Inc. ? Vice President, Investor Relations Bob Fireman MariMed Inc. ? Chief Executive Officer Tim Shaw MariMed Inc. ? Chief Operating Officer Jon Levine MariMed Inc. ? Chief Financial Officer Conference Call Participants Andrew
March 21, 2022	EX-99.1	Press release, dated March 16, 2022, announcing financial results for the year ended December 31, 2021. EX-99.1 2 ex99-1.htm Exhibit 99.1
March 16, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 MARIMED INC. (Exact
March 16, 2022	EX-10.18	Membership Interest Purchase Agreement, dated December 31, 2021, between MariMed Advisors Inc. and Jennifer DiPietro (incorporated by reference to Exhibit 10.18 to the Registrant's Annual Report on Form 10-K, filed March 16, 2022 with the SEC). Exhibit 10.18 THE COMPANY HAS OMITTED THE EXHIBITS AND/OR SCHEDULES FROM THE MEMBERSHIP INTEREST PURCHAE AGREEMENT CONTAINED IN EXHIBIT 10.18 BECAUSE THEY ARE NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL
March 16, 2022	EX-21.1	List of subsidiaries EXHIBIT 21.1 List of Subsidiaries: MariMed Advisors Inc. (formed in Massachusetts) Mia Development LLC (formed in Massachusetts) Mari Holdings IL LLC (formed in Massachusetts) Mari Holdings MD LLC (formed in Massachusetts) Mari Holdings NJ LLC (formed in New Jersey) Mari Holdings NV LLC (formed in Massachusetts) Mari Holdings Metropolis LLC (formed in Massachusetts) Mari Holdings Mt. Vernon LLC (f
March 16, 2022	EX-10.17	Membership Interest Purchase Agreement, dated December 31, 2021, between the Registrant and Jennifer DiPietro, Susan Zimmerman and Sophia Leonard-Burns (incorporated by reference to Exhibit 10.17 to the Registrant's Annual Report on Form 10-K, filed March 16, 2022 with the SEC). Exhibit 10.17 THE COMPANY HAS OMITTED THE EXHIBITS AND/OR SCHEDULES FROM THE MEMBERSHIP INTEREST PURCHAE AGREEMENT CONTAINED IN EXHIBIT 10.17 BECAUSE THEY ARE NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL
January 5, 2022	EX-99.1	MariMed Announces Agreement to Acquire Kind Therapeutics USA, LLC, A Maryland Licensed Vertically Integrated Cannabis Business Exhibit 99.1 MariMed Announces Agreement to Acquire Kind Therapeutics USA, LLC, A Maryland Licensed Vertically Integrated Cannabis Business NORWOOD, Mass., Jan. 5, 2022 ? MariMed Inc. (OTCQX: MRMD) (?MariMed? or the ?Company?), a leading multi-state cannabis operator focused on improving lives every day, today announced that it has entered into a definitive agreement to acquire Kind Therapeutics U
January 5, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2021 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporati
November 18, 2021	8-K	Regulation FD Disclosure, Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporati
November 18, 2021	EX-99.2	Transcript of investor conference call held on November 16, 2021. Exhibit 99.2
November 18, 2021	EX-99.1	Press release, dated November 15, 2021, announcing financial results for the three and nine month periods ended September 30, 2021. EX-99.1 2 ex99-1.htm Exhibit 99.1
November 15, 2021	EX-10.7.1	Amendment to the Amended and Restated 2018 Stock Award and Incentive Plan, effective as of September 23, 2021 (incorporated by reference to Exhibit 10.7.1 to the Registrant's Quarterly Report on Form 10-Q, filed November 15, 2021 with the SEC). Exhibit 10.7.1 AMENDMENT TO THE MARIMED INC. 2018 STOCK AWARD AND INCENTIVE PLAN (this ?Amendment?) Effective Date: September 23, 2021 A. Article III, Section 3.1 of the MariMed Inc. 2018 Stock Award and Incentive Plan (the ?Plan?) is hereby amended as follows: 3.1 Common Stock Authorized. Subject to the provisions of this Article and Article XI, the total aggregate number of shares of Common Stoc
November 15, 2021	EX-10.19	Form of the First Amendment to the Employment Agreement, effective as of September 22, 2021, between MariMed Inc. and each of Robert Fireman, Jon R. Levine, and Timothy Shaw (q) EX-10.19 5 ex10-19.htm Exhibit 10.19 MariMed Inc. FIRST AMENDMENT TO EMPLOYMENT AGREEMENT Effective Date: September 22, 2021 This First Amendment to the Employment Agreement (this “Agreement”) is between MARIMED INC., a Delaware corporation (the “Company” or “MariMed”), and [NAME OF EMPLOYEE], an individual (the “Executive”). WHEREAS, the Company and the Executive entered into an Employment Agreem
November 15, 2021	EX-10.20	Form of Stock Option Agreement, dated July 9, 2021 Granted under the Amended and Restated 2018 Stock Award and Incentive Plan, as amended, dated July 9, 2021, with each of Robert Fireman, Jon R. Levine, and Timothy Shaw (incorporated by reference to Exhibit 10.20 to the Registrant's Quarterly Report on Form 10-Q, filed November 15, 2021 with the SEC). Exhibit 10.20 MARIMED INC. Stock Option Agreement (this ?Agreement?) Dated: (?Grant Date?) MariMed Inc., a Delaware corporation (the ?Company?), in accordance with the Company?s Amended and Restated 2018 Stock Award and Incentive Plan (the ?Plan?) hereby grants to (the ?Optionee?), a stock option to purchase a total of shares of the Company?s Common Stock, par value $.001 per share (the ?Common St
November 15, 2021	EX-10.22	Settlement Agreement and General Release, dated August 19, 2021, between the Registrant and Thomas Kidrin (incorporated by reference to Exhibit 10.22 to the Registrant's Quarterly Report on Form 10-Q, filed November 15, 2021 with the SEC). Exhibit 10.22
November 15, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 MARIMED INC. (Exact Na
November 15, 2021	EX-3.1.6	Certificate of Amendment to the Certificate of Incorporation of the Company as filed with the Secretary of State of Delaware on September 24, 2021 (incorporated by reference to Exhibit 3.1.6 to the Company’s Quarterly Report on Form 10-Q, filed on November 15, 2021 with the SEC). Exhibit 3.1.6
November 15, 2021	EX-3.1.5	Certificate of Amendment to the Certificate of Incorporation of the Company as filed with the Secretary of State of Delaware on April 25, 2017, effective as of May 1, 2017 (incorporated by reference to Exhibit 3.1.5 to the Company’s Quarterly Report on Form 10-Q, filed on November 15, 2021 with the SEC). Exhibit 3.1.5
September 28, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2021 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporat
August 19, 2021	EX-99.1	MariMed Reports Strong Second Quarter 2021 Earnings Revenue Increased to $32.6 million, a 239% Increase Year Over Year EBITDA Increased to $12.3 million, a 440% Increase Year Over Year Raises Guidance for Revenue and EBITDA for Full Year 2021, and Ad EX-99.1 2 ex99-1.htm Exhibit 99.1 MariMed Reports Strong Second Quarter 2021 Earnings Revenue Increased to $32.6 million, a 239% Increase Year Over Year EBITDA Increased to $12.3 million, a 440% Increase Year Over Year Raises Guidance for Revenue and EBITDA for Full Year 2021, and Adds Adjusted EBITDA NORWOOD, Mass., August 16, 2021 - MariMed, Inc. (OTCQX: MRMD) (“MariMed” or the “Company”), a lea
August 19, 2021	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2021 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporation
August 19, 2021	EX-99.2	MariMed Inc. Second Quarter 2021 Earnings Call Event Date/Time: August 17, 2021 — 8:00 a.m. E.T. Length: 35 minutes Exhibit 99.2 MariMed Inc. Second Quarter 2021 Earnings Call Event Date/Time: August 17, 2021 ? 8:00 a.m. E.T. Length: 35 minutes Corporate participants Bob Fireman MariMed Inc. ? Founder & CEO Jon Levine MariMed Inc. ? Founder & CFO Conference Call Participants Glenn Mattson Ladenburg Thalmann ? Analyst Kyle Bauser Colliers Securities ? Analyst Eric Des Lauriers Craig-Hallum Capital Group ? Analys
August 17, 2021	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14a INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14a INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ]
August 16, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 MARIMED INC. (Exact Name of
July 23, 2021	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14a INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14a INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ]
July 9, 2021	EX-10.17	Employment Agreement between MariMed Inc. and Jon R. Levine, dated July 9, 2021 (s) Exhibit 10.17 MariMed Inc. EMPLOYMENT AGREEMENT Effective Date: July 1, 2021 This Employment Agreement (this ?Agreement?) is between MARIMED INC., a Delaware corporation (the ?Company? or ?MariMed?), and JON R. LEVINE, an individual (the ?Executive?). WHEREAS, the Executive currently serves the Company as Chief Financial Officer and in related capacities; and. WHEREAS, the Company seeks to continu
July 9, 2021	EX-10.18	Employment Agreement between MariMed Inc. and Timothy Shaw, dated July 9, 2021 (s) Exhibit 10.18 MariMed Inc. EMPLOYMENT AGREEMENT Effective Date: July 1, 2021 This Employment Agreement (this ?Agreement?) is between MARIMED INC., a Delaware corporation (the ?Company? or ?MariMed?), and TIMOTHY SHAW, an individual (the ?Executive?). WHEREAS, the Executive currently serves the Company as Chief Operating Officer and in related capacities; and. WHEREAS, the Company seeks to continue
July 9, 2021	EX-10.16	Employment Agreement between MariMed Inc. and Robert Fireman, dated July 9, 2021 (s) EX-10.16 2 ex10-16.htm Exhibit 10.16 MariMed Inc. EMPLOYMENT AGREEMENT Effective Date: July 1, 2021 This Employment Agreement (this “Agreement”) is between MARIMED INC., a Delaware corporation (the “Company” or “MariMed”), and ROBERT FIREMAN, an individual (the “Executive”). WHEREAS, the Executive currently serves the Company as Chief Executive Officer and in related capacities; and. WHEREAS, the
July 9, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2021 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporation) F
May 20, 2021	EX-99.1	MariMed Q1 2021 Results Reflect Highest Core Cannabis Revenue and Profitability Core Cannabis Revenue Increased 230% to $24.6m, EBITDA Increased 764% to $7.6m Q1 2021 vs. Q1 2020 Significantly Strengthened Balance Sheet and Improved Liquidity to Supp Exhibit 99.1 MariMed Q1 2021 Results Reflect Highest Core Cannabis Revenue and Profitability Core Cannabis Revenue Increased 230% to $24.6m, EBITDA Increased 764% to $7.6m Q1 2021 vs. Q1 2020 Significantly Strengthened Balance Sheet and Improved Liquidity to Support Future Growth Conference Call to be Held on May 18th at 9:00 a.m. EDT NORWOOD, Mass., May 17, 2021 - MariMed, Inc. (OTCQX: MRMD) (?Ma
May 20, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2021 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporation) F
May 20, 2021	EX-99.2	MariMed Inc. First Quarter 2021 Financial Results May 18, 2021 — 9:00 a.m. E.T. Length: 30 minutes EX-99.2 3 ex99-2.htm Exhibit 99.2 FINAL TRANSCRIPT MariMed Inc. First Quarter 2021 Financial Results May 18, 2021 — 9:00 a.m. E.T. Length: 30 minutes “While Cision has used commercially reasonable efforts to produce this transcript, it does not represent or warrant that this transcript is error-free. Cision will not be responsible for any direct, indirect, incidental, special, consequential, loss
May 17, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended March 31, 2021 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 MARIMED INC. (Exact Name o
April 28, 2021	424B3	22,645,215 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-255338 22,645,215 Shares of Common Stock This prospectus (this ?Prospectus?) relates to the sale, from time to time, by certain stockholders (the ?Selling Stockholders?) of up to an aggregate of 22,645,215 shares of MariMed Inc. common stock, par value $.001 per share (?Common Stock?) as follows: 750,000 shares which may be issued upon the exer
April 27, 2021	CORRESP	MARIMED INC. 10 Oceana Way Norwood, Massachusetts 02062 April 27, 2021 MARIMED INC. 10 Oceana Way Norwood, Massachusetts 02062 April 27, 2021 FILED VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Technology Washington, DC 20549 Attn: Mr. Mitchell Austin, Staff Attorney Re: MariMed Inc. (the ?Company?) Registration Statement on Form S-3, SEC File No. 333-255338 (the ?Registration Statement?) Dear Mr. Austin: In conn
April 19, 2021	S-3	- AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON APRIL 19, 2021 REGISTRATION NO.
April 1, 2021	EX-10.1	Amendment Agreement dated April 1, 2021, between SYYM LLC, as noteholder and collateral agent, and MariMed, Inc. and MariMed Hemp, Inc., as co-borrowers (r) EX-10.1 3 ex10-1.htm Exhibit 10.1 AMENDMENT AGREEMENT This Amendment Agreement (the “Agreement”), dated as of April 1, 2021, is made by and between SYYM LLC, as noteholder and collateral agent (the “Holder”), MariMed, Inc. (“MariMed”) and MariMed Hemp, Inc., as co-borrowers (individually, a “Borrower” and collectively, the “Borrowers”). WHEREAS, the Holder and the Borrowers entered into a Facility
April 1, 2021	EX-4.1	Third Amended and Restated Promissory Note, dated April 1, 2021, in the principal amount of $3,211,653.84, issued by MariMed Hemp Inc. and MariMed Inc. to SYYM LLC (r) EX-4.1 2 ex4-1.htm Exhibit 4.1 Execution Version Original Issue Date: June 4, 2019 Reissuance Date: April 1, 2021 Principal Amount: $3,211,653.84 Third AMENDED AND RESTATED PROMISSORY NOTE THIS THIRD AMENDED AND RESTATED PROMISSORY NOTE is one of a series of duly authorized and validly issued Promissory Notes of MariMed Hemp Inc., a Delaware corporation (the “Company”) and MariMed Inc., a Delaware
April 1, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2021 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporation)
March 26, 2021	8-K	Regulation FD Disclosure, Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2021 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporation)
March 26, 2021	EX-99.1	MariMed Reports Record Fourth Quarter and Full Year 2020 Financial Results and Provides Full Year 2021 Guidance Achieves Record Results Driven by Continued Consolidation of Cannabis Operations Core Cannabis Revenue Increased 292% in Q4 2020 ($20.4m) Exhibit 99.1 MariMed Reports Record Fourth Quarter and Full Year 2020 Financial Results and Provides Full Year 2021 Guidance Achieves Record Results Driven by Continued Consolidation of Cannabis Operations Core Cannabis Revenue Increased 292% in Q4 2020 ($20.4m) and 207% in FY 2020 ($50.9 m) Reports Q4 2020 EBITDA of $7.7 Million and $16.3 Million for FY 2020 Secures Long Term Capital Partner – Co
March 26, 2021	EX-99.2	MariMed Inc. Fourth Quarter 2020 Financial Results Conference Call Event Date/Time: March 24, 2021 — 8:30 a.m. E.T. Length: 27 minutes EX-99.2 3 ex99-2.htm Exhibit 99.2 MariMed Inc. Fourth Quarter 2020 Financial Results Conference Call Event Date/Time: March 24, 2021 — 8:30 a.m. E.T. Length: 27 minutes Corporate participants Bob Fireman MariMed Inc. — Founder & Chief Executive Officer Jon Levine MariMed Inc. — Founder & Chief Financial Officer Conference Call Participants Russell Stanley Beacon Securities — Analyst 2 PRESENTATION
March 23, 2021	10-K	Annual Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 MARIMED INC. (Exact
March 23, 2021	EX-4.7	Amended and Restated Common Stock Purchase Warrant, dated March 18, 2021, issued by MariMed Inc. to Hadron Healthcare Master Fund (q) EX-4.7 2 ex4-7.htm Exhibit 4.7 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO A
March 23, 2021	EX-10.14	First Amendment to Securities Purchase Agreement, dated March 18, 2021, between MariMed Inc. and Hadron Healthcare Master Fund (q) Exhibit 10.14 Execution Version FIRST AMENDMENT TO SECURITIES PURCHASE AGREEMENT This First Amendment to Securities Purchase Agreement (this ?First Amendment?) is dated as of March 18, 2021, by and between MariMed Inc., a Delaware corporation (the ?Company?), and Hadron Healthcare Master Fund, a Cayman Islands exempted company (the ?Purchaser?). WHEREAS, the Company and the Purchaser are parties t
March 2, 2021	EX-3.1.4	Series C Convertible Preferred Stock Certificate of Designation as filed with the Secretary of State of Delaware on March 1, 2021 (incorporated by reference to Exhibit 3.1.4 to the Company’s Current Report on Form 8-K, filed on March 2, 2021 with the SEC). Exhibit 3.1.4
March 2, 2021	8-K	Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2021 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporation)
March 2, 2021	EX-99.1	MariMed Secures New Funding from Long-Term Capital Partner Capital Infusion to Strengthen Balance Sheet and Provide Funding for Strategic Acquisitions $46 Million Dollar Financing Facility to Accelerate Company Growth Strategy EX-99.1 5 ex99-1.htm Exhibit 99.1 MariMed Secures New Funding from Long-Term Capital Partner Capital Infusion to Strengthen Balance Sheet and Provide Funding for Strategic Acquisitions $46 Million Dollar Financing Facility to Accelerate Company Growth Strategy NORWOOD, Mass., March 2, 2021 - MariMed, Inc. (OTCQX: MRMD) (the “Company” or “MariMed”), a leading multi-state cannabis operator focused o
March 2, 2021	EX-4.7	Common Stock Purchase Warrant, dated March 2, 2021, issued by MariMed Inc. to Hadron Healthcare Master Fund. EX-4.7 3 ex4-7.htm Exhibit 4.7
March 2, 2021	EX-10.13	Securities Purchase Agreement, dated March 1, 2021, between MariMed Inc. and Hadron Healthcare Master Fund (p) EX-10.13 4 ex10-13.htm Exhibit 10.13
February 4, 2021	S-8	- AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON FEBRUARY 4, 2021. REGISTRATION NO. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MARIMED INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 27-4672745 (I.R.S. Employer
November 16, 2020	8-K	Regulation FD Disclosure, Results of Operations and Financial Condition, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2020 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporatio
November 16, 2020	EX-99.2	Transcript of investor conference call held on November 10, 2020. Exhibit 99.2
November 16, 2020	EX-99.1	Press release, dated November 9, 2020, announcing financial results for the three and nine months ended September 30, 2020. Exhibit 99.1
November 9, 2020	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 MARIMED INC. (Exact Na
October 26, 2020	EX-10.13	Note Extension Agreement, effective as of September 30, 2020, among Best Buds Funding LLC, as lender, and each of MariMed Inc., Mari Holdings MD LLC, and MariMed Advisors Inc., as the borrower parties (n) Exhibit 10.13
October 26, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2020 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporatio
October 26, 2020	EX-4.5	Amended and Restated Senior Secured Commercial Promissory Note, dated October 19, 2020, in the principal amount of $3,000,000, issued by MariMed Advisors, Inc. to Best Buds Funding LLC (m) Exhibit 4.5
October 26, 2020	EX-4.6	Common Stock Purchase Warrant, dated September 30, 2020, issued by MariMed Inc.to Best Buds Funding, LLC. and/or its designees (m) Exhibit 4.6
October 26, 2020	EX-4.4	Amended and Restated Senior Secured Commercial Promissory Note, dated October 19, 2020, in the principal amount of $5,845,000, issued by MariMed Advisors, Inc. to Best Buds Funding LLC (m) Exhibit 4.4
August 11, 2020	EX-99.1	MariMed Reports Strong Second Quarter Results Exhibit 99.1 MariMed Reports Strong Second Quarter Results NORWOOD, Mass., August 10, 2020 — MariMed Inc. (MRMD:OTCQX) (the “Company” or “MariMed”), a leading multi-state cannabis and hemp operator focused on health and wellness, today reported financial and operating results for the three and six months ended June 30, 2020. Second Quarter 2020 and YTD Financial Highlights: ● Core cannabis Revenue
August 11, 2020	8-K	Financial Statements and Exhibits, Other Events - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2020 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporation
August 10, 2020	10-Q	Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 MARIMED INC. (Exact Name of
July 23, 2020	EX-99.1	MariMed Announces Debt Restructuring Actions and Improved Revenues and Cash Flow Exhibit 99.1 MariMed Announces Debt Restructuring Actions and Improved Revenues and Cash Flow ● Closes $13.0 million mortgage-backed refinancing at 6.5% ● Retires $7.3 million of short-term higher rate debt ● Revenues and cash flow from consolidated cannabis operations continue to increase NORWOOD, Mass., July 23, 2020 — MariMed Inc. (OTCQX: MRMD) (the “Company” or MariMed), a leading multi-state
July 23, 2020	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2020 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporation)
June 30, 2020	EX-4.2	Common Stock Purchase Warrant, dated June 24, 2020, issued by MariMed Inc.to SYYM LLC (k) Exhibit 4.2
June 30, 2020	EX-10.1	Amendment Agreement dated June 24, 2020, between SYYM LLC, as noteholder and collateral agent, and MariMed Inc. and MariMed Hemp Inc., as co-borrowers (l) Exhibit 10.1
June 30, 2020	EX-4.1	Second Amended and Restated Promissory Note, dated June 24, 2020, in the principal amount of $8,811,653.84, issued by MariMed Hemp Inc. and MariMed Inc. to SYYM LLC (j) Exhibit 4.1
June 30, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2020 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporation)
May 28, 2020	EX-10.11	Note Extension Agreement, dated April 23, 2020, among Best Buds Funding LLC, as lender, and each of MariMed Inc., Mari Holdings MD LLC, and MariMed Advisors Inc., as the borrower parties. * Exhibit 10.11
May 28, 2020	10-Q	Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended March 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 MARIMED INC. (Exact Na
May 28, 2020	EX-4.1.4	12% Convertible Promissory Note, dated April 23, 2020, in the principal amount of $900,000, issued by MariMed Inc. to Best Buds Funding LLC (i) Exhibit 4.1.4
May 28, 2020	EX-4.1.3	Senior Secured Commercial Promissory Note, dated April 23, 2020, in the principal amount of $6,845,000, issued by MariMed Advisors, Inc. to Best Buds Funding LLC. * Exhibit 4.1.3
May 12, 2020	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2020 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporation) F
May 12, 2020	EX-99.1	MariMed Announces Preliminary First Quarter 2020 Results Total Revenues Increase 112% Year-Over-Year Exhibit 99.1 MariMed Announces Preliminary First Quarter 2020 Results - Total Revenues Increase 112% Year-Over-Year NORWOOD, Mass., May 12, 2020 — MariMed Inc. (MRMD:OTCQX) (the “Company” or MariMed), a leading multi-state cannabis and hemp operator focused on health and wellness, today announced preliminary, unaudited, select financial results for the three-month period ended March 31, 2020. Prel
May 11, 2020	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2020 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporation) F
April 29, 2020	10-K/A	Annual Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-5443
April 1, 2020	EX-21	List of Subsidiaries EXHIBIT 21 List of Subsidiaries: MariMed Advisors Inc. (formed in Massachusetts) Mia Development LLC (formed in Massachusetts) Mari Holdings IL LLC (formed in Massachusetts) Mari Holdings MD LLC (formed in Massachusetts) Mari Holdings NV LLC (formed in Massachusetts) Hartwell Realty Holdings LLC (formed in Massachusetts) iRollie LLC (formed in Massachusetts) ARL Healthcare Inc. (formed in Massachu
April 1, 2020	10-K	WORX / Worlds Online, Inc. 10-K - Annual Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 MARIMED INC. (Ex
March 17, 2020	NT 10-K	WORX / Worlds Online, Inc. NT 10-K - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 Commission File Number 0-54433 NOTIFICATION OF LATE FILING (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-CEN [ ] Form N-CSR For Period Ended: December 31, 2019 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
February 28, 2020	EX-4.1	Promissory Note, dated February 27, 2020, in the principal amount of $3,742,500, issued by MariMed Inc. to Navy Capital Green Fund, LP (h) Exhibit 4.1
February 28, 2020	EX-3.2	Certificate Eliminating the Series A Preferred Stock as filed with the Secretary of State of Delaware on February 27, 2020 (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K, filed on February 28, 2020 with the SEC). Exhibit 3.2
February 28, 2020	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2020 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporati
February 28, 2020	EX-4.2	Promissory Note, dated February 27, 2020, in the principal amount of $675,000, issued by MariMed Inc. to Navy Capital Green Co-Invest Fund, LLC (h) Exhibit 4.2
February 28, 2020	EX-10.1	Exchange Agreement, dated as of February 27, 2020, among MariMed Inc., Navy Capital Green Management, LLC, a Delaware limited liability company, as discretionary investment manager of Navy Capital Green Fund, LP, and Navy Capital Green Co-Invest Fund, LLC. (h) Exhibit 10.1
February 28, 2020	EX-3.1	Series B Convertible Preferred Stock Certificate of Designation as filed with the Secretary of State of Delaware on February 27, 2020 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed on February 28, 2020 with the SEC). Exhibit 3.1
February 12, 2020	EX-4.1	Amended and Restated Promissory Note, dated February 10, 2020, in the principal amount of $11,500,000, issued by MariMed Hemp Inc. and MariMed Inc. (f) Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE (IF ANY) HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTI
February 12, 2020	EX-10.1	Amendment Agreement, dated as of February 10, 2020, between SYYM LLC, as noteholder and collateral agent, and MariMed Inc. and MariMed Hemp Inc., as co-borrowers (g) Exhibit 10.1 AMENDMENT AGREEMENT This Amendment Agreement (the “Agreement”), dated as of February 10, 2020, is made by and between SYYM LLC, as noteholder and collateral agent (the “Holder”), MariMed, Inc. (“MariMed”) and MariMed Hemp, Inc., as co-borrowers (the “Borrowers”) and each other Person executing this Agreement as a “Loan Party.” WHEREAS, the Holder and the Borrowers entered into a Facil
February 12, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2020 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporati
February 7, 2020	EX-99.1	MARIMED PROVIDES UPDATE ON GENCANNA GLOBAL, INC. EX-99.1 2 ex99-1.htm Exhibit 99.1 MARIMED PROVIDES UPDATE ON GENCANNA GLOBAL, INC. NORWOOD, Mass., February 6, 2020 - MariMed Inc. (MRMD:OTCQX) (the “Company” or “MariMed”), a leading multi-state cannabis and hemp operator focused on health and wellness, today issued a statement regarding the recent development that GenCanna Global, Inc. (“GenCanna”), a vertically-integrated producer of hemp and h
February 7, 2020	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2020 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporatio
January 21, 2020	CORRESP	WORX / Worlds Online, Inc. CORRESP - - 10 Oceana Way Norwood, MA 02062 844-244-0200 marimedinc.com January 21, 2020 Filed via EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Technology 100 F Street, NE Washington, D.C. 20549 Attn: Inessa Kessman, Senior Staff Accountant Robert Littlepage, Accounting Branch Chief Re: MariMed Inc. Form 10-K for the Fiscal Year Ended December 31, 2018 (“10-
January 6, 2020	CORRESP	WORX / Worlds Online, Inc. CORRESP - - January 6, 2020 Filed via EDGAR United States Securities and Exchange Commission 100 F Street, NE Washington, D.
November 29, 2019	EX-10.2	Form of Stock Option Agreement, dated September 27, 2019, with each of David R. Allen, Eva Selhub, M.D., and Edward J. Gildea (e)
November 29, 2019	10-Q	WORX / Worlds Online, Inc. 10-Q - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended September 30, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 MARIMED INC. (Exac
November 13, 2019	NT 10-Q	WORX / Worlds Online, Inc. NT 10-Q - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 Commission File Number 0-54433 NOTIFICATION OF LATE FILING (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-CEN [ ] Form N-CSR For Period Ended: September 30, 2019 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
October 22, 2019	EX-99.2	Press Release dated October 21, 2019.
October 22, 2019	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2019 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporatio
October 22, 2019	EX-99.1	Amended and Restated Membership Interest Purchase Agreement, dated as of October 1, 2018, by and among (i) the Company, (ii) Mari Holdings, KPG Anna and KPG Harrisburg, and (iii) Roseann Naumovski, Gorgi Naumovski and Brad Galli.
September 30, 2019	8-K	Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2019 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporat
September 30, 2019	EX-99.1	2019 Annual Meeting of Stockholders Presentation.
August 26, 2019	DEF 14A	Amended and Restated 2018 Stock Award and Incentive Plan (d) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14a INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ]
August 9, 2019	10-Q	WORX / Worlds Online, Inc. 10-Q - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended June 30, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 MARIMED INC. (Exact Nam
June 28, 2019	EX-99.1	Press release dated June 25, 2019.
June 28, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2019 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporation)
June 11, 2019	EX-99.1	Resignation letter from Thomas Kidrin dated June 5, 2019
June 11, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2019 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporation) F
June 10, 2019	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2019 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporation) F
May 23, 2019	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2019 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporation) F
May 10, 2019	10-Q	WORX / Worlds Online, Inc. 10-Q Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended March 31, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 MARIMED INC. (Exact Na
April 16, 2019	10-K	WORX / Worlds Online, Inc. (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 MARIMED INC. (Ex
April 16, 2019	EX-21	List of Subsidiaries * EXHIBIT 21 List of Subsidiaries: MariMed Advisors Inc. (formed in Massachusetts) Mia Development LLC (formed in Massachusetts) Mari Holdings IL LLC (formed in Massachusetts) Mari Holdings MD LLC (formed in Massachusetts) Mari Holdings NV LLC (formed in Massachusetts) Hartwell Realty Holdings LLC (formed in Massachusetts) iRollie LLC (formed in Massachusetts) ARL Healthcare Inc. (formed in Massachu
April 1, 2019	NT 10-K	WORX / Worlds Online, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 0-54433 (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-CEN [ ] Form N-CSR For Period Ended: December 31, 2018 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q For the Transition Period Ended: Read Instruction (on back page) Before Preparing Form.
December 10, 2018	EX-16.1	Letter dated December 10, 2018 from L&L CPAs, P.A. 19720 Jetton Road, 3rd Floor Cornelius, NC 28031 Tel: 704-897-8336 Fax: 704-919-5089 December 10, 2018 U.
December 10, 2018	8-K	Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2018 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporatio
November 14, 2018	10-Q	WORX / Worlds Online, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended September 30, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 MARIMED INC. (Exac
November 14, 2018	EX-10.3	Rights Agreement dated November 7, 2018 between the Registrant and GenCanna Global, Inc. and others
November 14, 2018	EX-10.1	Subscription Agreement for Convertible Debentures between the Registrant and GenCanna Global, Inc. dated November 7, 2018
November 14, 2018	EX-10.4	Security and Pledge Agreement dated November 7, 2018 between the Registrant and GenCanna Global, Inc.
November 14, 2018	EX-10.2	Form of Subordinated Secured Convertible Debenture of GenCanna Global, Inc.
November 9, 2018	8-K	Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2018 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporatio
November 9, 2018	EX-10.3	Form of Securities Purchase Agreement between the Company and YA II PN, LTD. (c)
November 9, 2018	EX-10.2	Form of Secured Convertible Debenture of GenCanna Global, Inc. (c)
November 9, 2018	EX-10.4	Amended and Restated Registration Rights Agreement dated as of November 5, 2018 between the Company and YA II PN, LTD. (c)
November 9, 2018	EX-10.1	Form of Convertible Debenture issued by the Company (c)
November 7, 2018	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2018 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporatio
November 7, 2018	EX-99.1	MariMed Hires Cannabis Analyst Charles Finnie as Chief Strategy Officer MariMed Hires Cannabis Analyst Charles Finnie as Chief Strategy Officer ● Finnie to lead MariMed M&A, strategic investment, corporate strategy, investor relations ● Finnie sees biggest opportunity in undervalued US cannabis companies NORWOOD, MA– Nov.
August 14, 2018	10-Q	WORX / Worlds Online, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended June 30, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 MARIMED INC. (Exact Nam
June 19, 2018	8-K	Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2018 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporation)
May 15, 2018	10-Q	WORX / Worlds Online, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended March 31, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 MARIMED INC. (Exact Na
April 2, 2018	10-K	WORX / Worlds Online, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 MARIMED INC. (Ex
April 2, 2018	EX-21	List of Subsidiaries EXHIBIT 21 List of Subsidiaries: MariMed Advisors Inc. (formed in Massachusetts) Mia Development LLC (formed in Massachusetts) Mari Holdings IL LLC (formed in Massachusetts) Mari Holdings MD LLC (formed in Massachusetts) Mari Holdings NV LLC (formed in Massachusetts) Hartwell Realty Holdings LLC (formed in Massachusetts)
March 14, 2018	8-K	Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2018 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporation)
December 26, 2017	EX-10.1	Secured Commercial Promissory Note of MariMed Advisors Inc. dated December 19, 2017 due June 18, 2017.
December 26, 2017	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2017 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction (Commission (IRS Employer of incorporati
November 14, 2017	10-Q	WORX / Worlds Online, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended September 30, 2017 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 MARIMED INC. (Exac
August 15, 2017	NT 10-Q	Worlds Online 0-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR For Period Ended: June 30, 2017 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form N-
August 15, 2017	10-Q	WORX / Worlds Online, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended June 30, 2017 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 MARIMED INC. (Exact Nam
July 26, 2017	8-K	Worlds Online FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2017 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction of incorporation) (Commission File Number) (
June 30, 2017	8-K	Worlds Online FORM 8K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2017 MARIMED INC. (Exact name of registrant as specified in its charter) Delaware 0-54433 27-4672745 (State or other jurisdiction of incorporation) (Commission File Number) (
May 15, 2017	EX-10	Membership Interest Purchase Agreement by and among Sigal Consulting, LLC, MariMed Inc., MariMed Advisors Inc., Robert Fireman, Gerald J. McGraw Jr., Jon R. Levine, James E. Griffin Jr. and Timothy Shaw MEMBERSHIP INTEREST PURCHASE AGREEMENT by and among SIGAL CONSULTING, LLC, a Massachusetts limited liability company, MARIMED INC.
May 15, 2017	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended March 31, 2017 ( ) TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended March 31, 2017 ( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 MARIMED INC. (Exact Na
April 17, 2017	EX-3	Amended Certificate of Incorporation of the Company (b) CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF WORLDS ONLINE INC. It is hereby certified that: 1. The name of the corporation (hereinafter called the "corporation") is Worlds Online Inc. 2. The certificate of incorporation of the corporation is hereby amended by striking out Article FOURTH thereof and by substituting in lieu of said Article the following new Article: "FOURTH: (A) The
April 17, 2017	EX-21	List of Subsidiaries* EXHIBIT 21 List of Subsidiaries Marimed Advisors Inc. (formed in Massachusetts) Mia Development LLC (formed in Massachusetts) Mari Holdings IL LLC (formed in Massachusetts) Mari Holdings NV LLC (formed in Massachusetts)
April 17, 2017	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24115 WORLDS ONLINE INC.
April 3, 2017	NT 10-K	Worlds Online 0-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form N-SAR For Period Ended: December 31, 2016 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Transition Report on For
February 6, 2017	DEF 14C	Amended Certificate of Incorporation of the Company (b) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ? Preliminary Information Statement ? Confidential, for use of the Commission only (as permitted by Rule 14c-5(d)(2)) ? Definitive Information Statement WORLDS ONLINE INC. (Name of Registra
January 26, 2017	PRE 14C	Worlds Online 14C INFORMATION STATEMENT THIS INFORMATION STATEMENT IS BEING PROVIDED TO YOU BY THE BOARD OF DIRECTORS OF THE COMPANY WE ARE NOT ASKING YOU FOR A PROXY AND YOU ARE REQUESTED NOT TO SEND US A PROXY WORLDS ONLINE INC.
December 22, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended September 30, 2016 ( ) TRANSITION REPORT PURS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended September 30, 2016 ( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 0-54433 WORLDS ONLINE INC.

MRMD / MariMed Inc. - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

الإحصائيات الأساسية

SEC Filings

SEC Filings (Chronological Order)

Other Listings